An FDA advisory panel voted 9-0 on June 18, 2026, to recommend Moderna’s influenza vaccine mFLUSIVA for approval.
The vaccine, called mRNA-1010, is the first mRNA-based seasonal influenza vaccine to reach this advisory stage.
Per BioPharma International, the 9-0 unanimous vote sets the stage for a full FDA approval decision expected in August 2026.
What the FDA 9-0 Moderna Influenza Vaccine Vote Means for Approval
Advisory committee votes are not binding, but a 9-0 result sends a strong signal to the full FDA agency.
The FDA typically follows advisory panel recommendations, making August approval highly likely but not guaranteed.
mFLUSIVA was evaluated for efficacy in adults aged 50 and older, the group most at risk from influenza.
Moderna’s mRNA vaccine uses the same platform that powered its successful COVID-19 vaccine, approved in 2020.
The influenza vaccine would give Moderna its first product beyond the COVID vaccine in the mRNA category.
An August approval would make mFLUSIVA available for the fall 2026 flu season, with millions of doses expected.
What Is mFLUSIVA and How Does Moderna’s mRNA Influenza Vaccine Work?
mFLUSIVA, also known as mRNA-1010, encodes four flu antigens: two influenza A strains and two influenza B strains.
Unlike traditional flu vaccines made from inactivated viruses, mRNA vaccines instruct cells to make viral proteins.
The immune system then builds defenses against those proteins, training it to recognize future flu infections.
mRNA vaccines can be reformulated far faster than egg-based or cell-based vaccines as flu strains evolve seasonally.
That speed advantage could allow mFLUSIVA to better match circulating strains if a late-season mutation emerges.
Per Moderna, mFLUSIVA showed strong immune response rates comparable to standard flu vaccines in Phase 3 trials.
The FDA Agency Drama Behind the Moderna Vaccine Approval Path
The path to today’s 9-0 vote was not smooth: FDA’s Vinay Prasad issued a refusal-to-file letter in February 2026.
That letter suggested the FDA would not even accept the mFLUSIVA application for full review.
Prasad’s letter triggered significant backlash from the biotech industry, vaccine advocates, and public health experts.
After the backlash, the FDA reversed course and agreed to accept and review the Moderna vaccine application.
The reversal led directly to today’s 9-0 advisory panel recommendation, a dramatic turnaround from February.
The episode exposed internal FDA tensions over mRNA vaccine approvals that go beyond standard science review.
How Moderna’s mRNA Flu Vaccine Compares to Traditional Flu Shots
Standard flu vaccines are produced using fertilized chicken eggs, a process that takes 4 to 6 months each year.
mRNA vaccines can be designed and produced in weeks once the target strain sequences are known.
High-dose traditional vaccines for adults over 65 exist today; mFLUSIVA targets a broader adult 50-plus cohort.
Early data shows mFLUSIVA matches the immunogenicity of approved flu vaccines across multiple strain types.
The approval would advance biotech and health innovation at a time when mRNA technology is expanding rapidly.
If effective long-term, mRNA flu vaccines could replace egg-based shots and permanently modernize flu prevention.
What Comes Next for the Moderna mRNA Flu Vaccine After the FDA Vote
The full FDA will now review the advisory panel recommendation and is expected to issue a decision by August 2026.
If approved, Moderna will need to scale manufacturing to produce enough doses for the fall 2026 flu season.
The vaccine would initially be recommended for adults 50 and older, with potential expansion to younger adults later.
Insurance coverage will depend on CDC’s Advisory Committee on Immunization Practices issuing a recommendation.
Walgreens, CVS, and major pharmacy chains are expected to offer mFLUSIVA alongside traditional flu shots in fall.
A successful launch validates mRNA as a platform for annual vaccines, per health tech investment trends.
Related Articles
Trust Post Desk
A journalist and editor at TrustPost.org covering world and national news, technology updates and human-interest stories. They check every fact, interview sources in person or online, and aim to deliver clear, accurate reporting. Their work ranges from breaking news to in-depth features and daily newsletters. Outside the newsroom, they follow emerging trends and engage with readers on social media.
